Asian Journal of Sports Medicine

Published by: Kowsar

Long Term and Intensive Use of Ophthalmic Topical Corticosteroids and the Risk of Positive Doping Test in Athletes: A Case Report

Tohid Seif Barghi 1 , 2 , * , Farzad Kobarfard 3 , Ahmad Hashemian 2 and Jayran Zebardast 4
Authors Information
1 Sports Medicine Research Center, Tehran University of Medical Sciences, Tehran, IR Iran
2 Medical Committee, Football Federation Islamic Republic of Iran (FFIRI), Tehran, IR Iran
3 Department of Medicinal Chemistry, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Msn Student of Electronic Learning in Medical Education, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Asian Journal of Sports Medicine: September 01, 2015, 6 (3); e24621
  • Published Online: September 23, 2015
  • Article Type: Case Report
  • Received: October 16, 2014
  • Accepted: November 17, 2014
  • DOI: 10.5812/asjsm.24621

To Cite: Seif Barghi T, Kobarfard F, Hashemian A, Zebardast J. Long Term and Intensive Use of Ophthalmic Topical Corticosteroids and the Risk of Positive Doping Test in Athletes: A Case Report, Asian J Sports Med. 2015 ; 6(3):e24621. doi: 10.5812/asjsm.24621.

Copyright © 2015, Sports Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
  • 1.
  • 2. Haaga M, Kaila T, Salminen L, Ylitalo P. Systemic and ocular absorption and antagonist activity of topically applied cyclopentolate in man. Pharmacol Toxicol. 1998; 82(1): 19-22[PubMed]
  • 3. Kaila T, Huupponen R, Salminen L, Iisalo E. Systemic absorption of ophthalmic cyclopentolate. Am J Ophthalmol. 1989; 107(5): 562-4[PubMed]
  • 4. Fraunfelder FT, Meyer SM. Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine. Am J Ophthalmol. 1985; 99(3): 362-3[PubMed]
  • 5. Fraunfelder FT, Scafidi AF. Possible adverse effects from topical ocular 10% phenylephrine. Am J Ophthalmol. 1978; 85(4): 447-53[PubMed]
  • 6. Hakim OJ, Orton RB, Cadera W. Topical 2.5% and 5% phenylephrine: comparison of effects on heart rate and blood pressure. Can J Ophthalmol. 1990; 25(7): 336-9[PubMed]
  • 7. Meyer SM, Fraunfelder FT. 3. Phenylephrine hydrochloride. Ophthalmology. 1980; 87(11): 1177-80[PubMed]
  • 8. Elibol O, Alcelik T, Yuksel N, Caglar Y. The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants. Acta Ophthalmol Scand. 1997; 75(2): 178-80[PubMed]
  • 9. Ogut MS, Bozkurt N, Ozek E, Birgen H, Kazokoglu H, Ogut M. Effects and side effects of mydriatic eyedrops in neonates. Eur J Ophthalmol. 1996; 6(2): 192-6[PubMed]
  • 10. Stoelting R, Miller R. Basics of Anestesia. 2007;
  • 11. Feldman MA, Patel A. Miller's anesthesia. 2010; : 2357-88
  • 12. Raw D, Mostafa SM. Drugs and the eye. Br J Anaesth. 2001; 6: 161-5
  • 13. McGhee CN. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992; 76(11): 681-4[PubMed]
  • 14. Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002; 109(10): 1887-91[PubMed]
  • 15. Roarty JD. Neonataland Pediatric Pharmacology. 2005; : 340-8
  • 16. Hopkins GA, Lyle WM. Potential systemic side effects of six common ophthalmic drugs. J Am Optom Assoc. 1977; 48(10): 1241-5[PubMed]
  • 17. Roters S, Aspacher F, Diestelhorst M. The influence of dexamethasone 0.1% eye drops on plasma cortisol and ACTH concentrations after cataract surgery. Ophthalmologica. 1996; 210(4): 211-4[PubMed]
  • 18. Ozerdem U, Levi L, Cheng L, Song MK, Scher C, Freeman WR. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol. 2000; 130(2): 240-1[PubMed]
  • 19. Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr (Phila). 2004; 43(1): 99-101[PubMed]
  • 20. Wolthers OD. Growth suppression caused by corticosteroid eye drops. J Pediatr Endocrinol Metab. 2011; 24(5-6): 393-4[PubMed]
  • 21. Proksch JW, Lowe ER, Ward KW. Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys. Drug Metab Dispos. 2011; 39(7): 1181-7[DOI][PubMed]
  • 22. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002; 25(1): 33-55[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments